Abstract
The aim of this study was to find the maximum tolerated dose of epidoxorubicin as part of a regimen with vinorelbine at the dose of 25 mg/m 2 on days 1 and 5, every 2 weeks in patients with advanced breast cancer. The optimal dose intensity of the two drugs was supported by administration of granulocyte colony stimulating factor (G-CSF) on days 7-12. Patients were treated with epidoxorubicin at three different dose levels (50-65-80 mg/m 2 on day 1 of each cycle). No dose limiting toxicity was observed in the first three patients (treated at the dose of 50 mg/m 2). We observed one case of dose limiting toxicity out of the 6 patients treated with 65 mg/m 2 and 3/3 cases among patients treated with 80 mg/m 2. We conclude that 65 mg/m 2 is the maximum tolerated dose of epidoxorubicin in this regimen, which is also able to maintain adequate dose intensities.
Original language | English |
---|---|
Pages (from-to) | 326-330 |
Number of pages | 5 |
Journal | Journal of Chemotherapy |
Volume | 10 |
Issue number | 4 |
Publication status | Published - 1998 |
Keywords
- Advanced breast cancer
- Breast cancer
- Epidoxorubicin
- Granulocyte colony stimulating factor
- Vinorelbine
ASJC Scopus subject areas
- Pharmacology (medical)
- Microbiology (medical)